Screening of hub genes and evaluation of the growth regulatory role of CD44 in metastatic prostate cancer

Abstract

Prostate cancer (PCa) is the most common cancer type in men worldwide. Currently, the management of metastatic PCa (mPCa) remains a challenge to urologists. The analysis of hub genes and pathways may facilitate the understanding of the molecular mechanism of PCa. In the present study, to identify the hub genes in the mPCa, the three datasets GSE3325, GSE6919 and GSE38241 were downloaded from the platform of the Gene Expression Omnibus and function enrichment analysis of differentially expressed genes (DEGs) was performed. A total of 168 DEGs were obtained and the DEGs were significantly enriched in 'cell junction' and 'cell adhesion', among others. The Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis demonstrated that DEGs were enriched in three pathways including 'focal adhesion', 'renal cell carcinoma' and 'Hippo signaling pathway'.

Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia

“…CD44 is a multifunctional cell surface adhesion receptor that is expressed in many cancers [including prostate cancer ( 43 )] and promotes the migration and invasion involved in metastases ( 44 , 45 ). It is a known prostate cancer stem cell marker ( 46 ) that has been nominated as a potential therapeutic target ( 47 ) and has been shown to play a role in chemo- and radiotherapy response and resistance in prostate cancer ( 48 , 49 ), nominating CD44 as a valuable marker and potential therapeutic target, requiring further in-depth investigations.…”